The thesis

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company with 18.9% revenue growth and 90.4% gross margin. The company's net margin is 100.8%, indicating strong profitability. Analyst consensus is BUY, but the Decifer score is 20, indicating watchlist status. The tension between strong financials and watchlist status makes the setup interesting.

Why now

The current macro context, including concerns about France debt and potential Fed hike cycle, may impact biotech stocks. Aurinia's strong revenue growth and margins may provide a buffer against sector-wide volatility.

What to watch

Revenue growth trajectory and margin sustainability over the next quarter will be key indicators of the company's performance. Any changes in analyst consensus rating or Decifer score will also be important to monitor.

Key risks

Valuation risk is present with a P/E of 7.3x, which may not fully reflect the company's growth prospects. Execution risk is also a concern, as the company's high net margin may not be sustainable if revenue growth slows.

Theme exposure